QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=B38F0E55D27DDEADFC7082A769BE0553;jsessionid=9F985B612266BCF7886925E7D55AEC9D;jsessionid=FFFA84BB16D04EBA1B3B8F39AFAF2C83;jsessionid=9D33DE5EA3B5B402E5AD4101F3C1ABC1;jsessionid=75B30480D04794F7E4E5983E47162430 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=B38F0E55D27DDEADFC7082A769BE0553;jsessionid=9F985B612266BCF7886925E7D55AEC9D;jsessionid=FFFA84BB16D04EBA1B3B8F39AFAF2C83;jsessionid=9D33DE5EA3B5B402E5AD4101F3C1ABC1;jsessionid=75B30480D04794F7E4E5983E47162430